The Cancer Letter

The leading source for information on the issues that shape oncology since 1973

Clinical Roundup

Anti-seizure drug fights aggressive childhood brain tumors, Stanford Medicine-led study shows

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
DOWNLOAD PDFTABLE OF CONTENTS

An existing anti-seizure drug slows the growth of a devastating group of childhood cancers, according to the results of a Stanford Medicine-led study. 

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

Clinical Roundup

Urine test may improve bladder cancer diagnosis and guide treatment decision, Stanford-led study finds

A simple urine test devised by researchers at Stanford Medicine and the VA Palo Alto Health Care System can diagnose people with bladder cancer more accurately than current standard methods. The test also allows physicians to not only assess the cancer’s response to treatment but to predict whether immunotherapy or chemotherapy is likely to be most effective for each patient.
In Brief

Ronald McDonald Community Floor opens in honor of Childhood Cancer Awareness Month

Ronald McDonald House New York announced the completion of its renovation of the Community Floor, a reimagined space designed to enhance the everyday experience of children and families staying at the House while their children receive treatment for serious illnesses. The project, which has transformed dining, kitchen, play, and program areas on the second floor of the House at 405 East 73rd Street, creates spaces where families can share meals, children can play and learn, and caregivers can find opportunities for connection, respite, and support.
Table of Contents

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account